STOCKHOLM - December 30, 2014. As a result of the share issue directed to and subscribed by Sino Biopharmaceutical Limited, a member of the Charoen Pokphand Group (CP Group), in accordance with the announcement on November 5, the number of series B shares in Karolinska Development AB has increased by 4,853,141.
Today, the last trading day of the month, there are in total 53,384,558 shares outstanding and 66,912,440 votes in Karolinska Development. Of these, 1,503,098 are series A shares with 15,030,980 votes and 51,881,460 are shares and votes of series B.
Karolinska Development AB (publ) discloses the information in this press release according to the Swedish Securities Markets Act and/or the Swedish Financial Trading Act. The information was provided for public release on December 30, 2014 at 9.00am.
For further information, please contact:
Bruno Lucidi, CEO, Karolinska Development AB
Phone: +46 (0) 8 524 860 70, e-mail: Bruno.lucidi@karolinskadevelopment.com
Help employers find you! Check out all the jobs and post your resume.
